Greenland Mines Ltd
Key Metrics
Market Snapshot
About
Greenland Mines Ltd (GRML) is a US-based company with an unconventional business model split between natural resources exploration and early-stage biotech development. Headquartered in Charlotte, North Carolina, it is known for its focus on mineral deposits in Greenland and its pursuit of gene therapies for neurological diseases.
The company's natural resources segment centers on exploring precious metals. Its primary mineral project is the Skaergaard site in Southeast Greenland, where it targets deposits containing palladium, gold, and platinum. This involves the assessment and development of these mining assets. Separately, the company maintains a biotechnology initiative focused on cell and gene therapy research. This includes developing KLTO-202 as a potential therapeutic for amyotrophic lateral sclerosis (ALS) and KLTO-101 aimed at Alzheimer's disease. The research pipeline also extends to therapies targeting Parkinson's disease and other age-related neurological disorders.
The company underwent a significant rebranding, changing its name from Klotho Neurosciences, Inc. to Greenland Mines Ltd in March 2026, reflecting its dual operational focus. This structure presents a unique combination of two distinct, capital-intensive, and long-development-cycle industries: hard asset mining and speculative biomedical research.